Adult Cystic Fibrosis Pulmonology Clinical Trials
Current Adult Cystic Fibrosis Pulmonology Clinical Trials
Study: ARCT-032
Study title: A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
NCT Number: NCT06747858
